LPCAT3 is essential for leukemia progression and represents a therapeutic vulnerability in AML
Open Access
- 3 September 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Blood Science
- Vol. 8 (3) , e00296
Abstract
Acute myeloid leukemia (AML) is a group of genetically and clinically heterogeneous malignancies characterized by clonal expansion of immature myeloid progenitors and profound disruption of normal hematopoiesis. Emerging evidence suggests that alterations in cellular homeostasis shape cancer progression. However, the mechanisms underlying AML progression remain largely unclear. Here, we identify lysophosphatidylcholine acyltransferase 3 (LPCAT3), a key enzyme of the Lands’ cycle, as a critical regulator of AML progression. Analysis of public transcriptomic datasets and patient-derived CD34 + cells revealed robust LPCAT3 overexpression in AML and an association between high LPCAT3 levels and inferior overall AML patient survival. Suppression of LPCAT3 by shRNA or CRISPR–Cas9 in MOLM-13 and THP-1 cells markedly impaired proliferation, induced apoptosis, and caused G0/G1 cell-cycle arrest. Conversely, enforced overexpression promoted cell survival. In xenograft murine models, LPCAT3 depletion reduced leukemic burden. RNA-seq following LPCAT3 loss showed that genes differentially expressed were significantly enriched in granulocyte chemotaxis–related pathways, suggesting a role of LPCAT3 in modulation of leukemic differentiation programs and microenvironmental interactions. Collectively, these data established that LPCAT3 as a previously unrecognized mediator of AML cell fitness and as a potential therapeutic target.Keywords
This publication has 65 references indexed in Scilit:
- LPCAT3—dependent remodeling of the phospholipids and lipid rafts is essential for vascular proinflammatory signaling and the development of atherosclerosisInflammation Research, 2025
- LPCAT3 regulates the immune infiltration and prognosis of ccRCC patients by mediating ferroptosis and endoplasmic reticulum stressDiscover Oncology, 2025
- Studying the cellular efficacy and tolerability of using CRISPR-gRNA ribonucleoprotein (RNP) complex for in-vitro knockdown of TRIB2 in acute myeloid leukaemia (AML) cells as preliminary clinical evaluationsMolecular Biology Reports, 2025
- Ferroptosis as a promising targeted therapy for triple negative breast cancerBreast Cancer Research and Treatment, 2024
- Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 StudiesDrug Safety, 2024
- Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applicationsCell, 2022
- CCL24 Signaling in the Tumor Microenvironment2021
- SLAMF1/CD150 in hematologic malignancies: Silent marker or active player?Clinical Immunology, 2019
- LXRs Regulate ER Stress and Inflammation through Dynamic Modulation of Membrane Phospholipid CompositionCell Metabolism, 2013
- Microenvironment Determines Lineage Fate in a Human Model of MLL-AF9 LeukemiaCancer Cell, 2008